Autologous CAR-T cells targeting CD22

Autologous CAR-T cells targeting CD22 are a form of chimeric antigen receptor (CAR) T cell therapy in which a patient's own (autologous) T lymphocytes are genetically engineered to express a synthetic receptor that specifically recognizes the B-cell surface antigen CD22. Upon reinfusion into the patient, these modified T cells bind to and kill malignant B cells expressing the CD22 antigen through direct cytotoxicity and cytokine release. This therapy is primarily being developed for relapsed or refractory B-cell malignancies such as acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL), especially in patients who have failed prior therapies including anti-CD19 treatments. Early-phase clinical studies have demonstrated promising complete remission rates with an acceptable safety profile[1][2]. The approach is part of a broader class of personalized immunotherapies designed to overcome resistance mechanisms like antigen escape.

Other names

CD22 CAR T-cellsCD-22 CAR T-cellsCD 22 CAR T-cellsautologous CD22 CAR T-cellsanti-CD22 CAR T-cellsanti-CD-22 CAR T-cellsanti-CD 22 CAR T-cells